Asha Therapeutics LLC has nominated a development candidate, ASHA-624, as a potential disease-modifying therapy for amyotrophic lateral sclerosis (ALS) with additional indications in chemotherapy-induced peripheral neuropathy, glaucoma, and traumatic brain and spinal cord injuries. ASHA-624 is expected to enter the clinic by year-end.
Researchers presented the development of a translational pharmacokinetic (PK)/receptor occupancy (RO) model of the tetravalent bispecific antibody (bsAb) CTX-8371 (Compass Therapeutics LLC) with the aim of investigating the possible effects of tetravalency compared to bivalency on RO and target internalization.
Analysis of the immune signatures of blood samples from patients with early-stage multiple sclerosis (MS) who were treatment naive has identified three distinct subtypes that have different disease trajectories and which respond differently to therapy.
Europe may still await its first disease-modifying Alzheimer’s drug after the EMA postponed its decision on Leqembi (lecanemab, Biogen Inc./Eisai Co. Ltd) on March 22, but leading members of the World Dementia Council were in an optimistic mood when they convened in London four days later. “We are working to make the inevitable happen earlier,” said Lenny Shallcross, executive director of WDC. “The inevitable will be rollout of medicines, rollout of better diagnostics and the improvement of care. All of those things over the next 10 years are inevitably going to happen.”
Deciphera Pharmaceuticals LLC has described serine/threonine-protein kinase ULK1 and/or ULK2 and/or leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has divulged MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of rheumatoid arthritis and radiographic axial spondyloarthritis (ankylosing spondylitis).
Scientists from Abbvie Deutschland GmbH & Co. KG and Abbvie Inc. have identified radiolabeled compounds capable of imaging and targeting microtubule-associated protein Tau (PHF-tau; MAPT) aggregates acting as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis of progressive supranuclear palsy.
Acurex Biosciences Corp. has synthesized phenothiazines acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.
Japan Tobacco Inc. has disclosed pyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, inflammatory bowel disease and more.
RSS
